CareCloud, Inc. Q4 FY2024 earnings call

Key Accomplishments in 2024

• Achieved record-breaking profitability with adjusted EBITDA rising to $24.1 million (56% YOY increase), net income at an all-time high of $7.9 million, and free cash flow reaching $13.2 million (nearly 250% YOY increase).
• Reached neutral earnings per share in Q4 2024, a pivotal milestone towards sustained profitability.

Series A Preferred Stock Conversion

• Converted Series A preferred shares to common stock at the redemption price of $25, including payment of accumulated dividends totaling about $11 million. This aligned interests of preferred and common shareholders and consolidated the capital structure.

AI-Driven Innovations

• Expanded cirrusAI Notes to multiple specialties (OB-GYN, general practice, etc.), enhancing clinical documentation and workflow efficiency.
• AI-powered advancements included summarization improving patient history review, plain note summarization streamlining revenue cycle processes, and denial management automation reducing manual claim processing.
• Introduced an AI-powered call center auditing and monitoring solution (deployed internally, market launch next quarter).
• Developed specialty-based EHR solutions for rheumatology, gastroenterology, etc., set to launch in Q2 2025.

Cost Management

• Reduced reliance on third-party contractors and optimized the global workforce to strengthen margins while maintaining scalability.

No specific product segment breakdown provided in the transcript.

Revenue

• Anticipates revenue in the range of $111 million to $114 million in 2025.

Adjusted EBITDA

• Projects adjusted EBITDA between $26 million and $28 million in 2025.

EPS

• Expects EPS to range between $0.10 and $0.13 in 2025, marking the first positive EPS since IPO in 2014.

M&A

• Re-entered the acquisition market with a small acquisition in March 2025, pursuing accretive deals aligned with long-term objectives, targeting medical billing companies struggling to scale and adapt to automation.

Risks

• Forward-looking statements are subject to various risks and uncertainties beyond control, which could cause actual results to differ materially from forward-looking statements.
• M&A execution risks: Need for disciplined approach to ensure accretive deals aligning with long-term objectives.
• Market and competitive risks: Changes in the healthcare technology market and competition could impact performance.

Q: Michael Kim inquired about revenue growth drivers and the M&A pipeline.

A: Stephen Snyder responded that revenue growth will come from upsells to existing clients, net new opportunities (including specialty EHRs and RCM), and tuck-ins from acquisitions. On M&A, CareCloud re-entered the acquisition market with a small acquisition in March, pursuing accretive deals targeting medical billing companies struggling to scale, with a disciplined approach to ensure alignment with long-term objectives.

Q: Jeffrey Cohen asked about the user base and the 2025 guide.

A: Stephen Snyder noted the user base is diversified geographically and by specialty, with most using the integrated platform. The 2025 guide reflects traditional organic growth, upselling existing clients, and potential M&A impact, with a disciplined approach to factor in attrition and additions.

Q: Allen Klee inquired about preferred stocks, including Series A conversion and future dividend payments.

A: Stephen Snyder explained that Series A preferred shares were converted at the redemption price, with remaining shares still outstanding and dividends paid. For Series B, dividends continue at 8.75%, with monthly payments in arrears, and potential for redemption or further conversions down the road. Annualized preferred dividends going forward are approximately $5.5 million, with monthly payments around $450,000.